This is a preview of subscription content, log in via an institution to check access.
Reference
Gershon N, et al. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Effectiveness and Resource Allocation : 28 Feb 2019. Available from: URL: https://doi.org/10.1186/s12962-019-0174-7
Rights and permissions
About this article
Cite this article
Trastuzumab for HER2-positive breast cancer too costly in Africa. PharmacoEcon Outcomes News 823, 31 (2019). https://doi.org/10.1007/s40274-019-5721-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5721-0